Lukas Moesgaard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lukas Moesgaard has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Morten Hostrup
Department of Nutrition, Exercise and Sports University of Copenhagen Copenhagen Denmark
8 shared publications - Søren Jessen
The August Krogh Section for Human Physiology, Department of Nutrition, Exercise and Sports University of Copenhagen Copenhagen Denmark
6 shared publications - Jens Bangsbo
Department of Nutrition, Exercise and Sports University of Copenhagen Copenhagen Denmark
4 shared publications - Atul Shahaji Deshmukh
Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark
3 shared publications - Roger Moreno-Justicia
Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark
3 shared publications Ben Stocks
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
2 shared publications
Latest Publications
- Open Access
- 12 September 2026
- Published by Springer Nature in Sports Medicine
- p. 1-13
Effects of Clenbuterol on Body Composition and Strength Following Resistance Training, Detraining, and Retraining in Healthy Adults: A Randomized Controlled Trial
Background: Clenbuterol, a potent β 2 -adrenoceptor agonist, is commonly used off-label in conjunction with resistance training to increase muscle mass and decrease fat mass. However, the long-term effects on body composition and strength with use and following discontinuation of use remain unexplored. Objective: The aim of the study was to investigate the effects of clenbuterol on body composition and strength during a resistance training intervention, as well as the long-term effects of prior use of clenbuterol during detraining and subsequent retraining in healthy young men and women. Methods: This randomized, double-blinded, placebo-controlled trial was conducted at the University of Copenhagen, Denmark, between March 2023 and March 2025. Thirty-two healthy men (26 ± 3 years; mean ± SD; n = 16) and women (25 ± 5 years; n = 16) completed 8 weeks of resistance training with daily ingestion of clenbuterol (80 μg) ( n = 16) or placebo ( n = 16). This was followed by 16 weeks of detraining and another 8 weeks of resistance training. Before the intervention and after each training and detraining period, body composition was assessed by dual-energy X-ray absorptiometry (DXA) and strength was assessed by leg press and bench press 1-repetition maximum (1RM). Results: Clenbuterol increased gains in lean mass (+ 1.7 kg, p < 0.001) and 1RM bench press (+ 6 kg, p < 0.001) and leg press (+ 16 kg, p = 0.001) during 8 weeks of resistance training compared with placebo, with a more pronounced effect in males than females (lean mass: p = 0.003; 1RM bench press: p < 0.001), whereas the decrease in fat mass did not differ between clenbuterol and placebo ( p = 0.614). Following cessation of clenbuterol, detraining decreased lean mass ( p < 0.001), 1RM bench press ( p < 0.001), and 1RM leg press ( p = 0.026) to a greater extent in the clenbuterol group, such that initial changes in lean mass ( p = 0.363) and 1RM bench press ( p = 0.834) no longer differed from placebo, whereas 1RM leg press remained elevated in the clenbuterol group ( p = 0.041). Retraining increased lean mass and 1RM leg press with no differences between the clenbuterol and placebo group (lean mass: p = 0.393; 1RM leg press: p = 0.662), whereas the increase in 1RM bench press was greater in the clenbuterol group (+ 3 kg, p = 0.047). Conclusion: Clenbuterol markedly augments training-induced gains in lean mass and strength. After discontinuation, prior clenbuterol exposure does not enhance retraining-induced lean mass gains, but some strength-related advantages persist. Trial Registration: ClinicalTrials.gov identifier, NCT05692856.
- 12 September 2026
- Published by Springer Nature in Sports Medicine
- p. 1-13
Open AccessEffects of Clenbuterol on Body Composition and Strength Following Resistance Training, Detraining, and Retraining in Healthy Adults: A Randomized Controlled Trial
Background: Clenbuterol, a potent β 2 -adrenoceptor agonist, is commonly used off-label in conjunction with resistance training to increase muscle mass and decrease fat mass. However, the long-term effects on body composition and strength with use and following discontinuation of use remain unexplored. Objective: The aim of the study was to investigate the effects of clenbuterol on body composition and strength during a resistance training intervention, as well as the long-term effects of prior use of clenbuterol during detraining and subsequent retraining in healthy young men and women. Methods: This randomized, double-blinded, placebo-controlled trial was conducted at the University of Copenhagen, Denmark, between March 2023 and March 2025. Thirty-two healthy men (26 ± 3 years; mean ± SD; n = 16) and women (25 ± 5 years; n = 16) completed 8 weeks of resistance training with daily ingestion of clenbuterol (80 μg) ( n = 16) or placebo ( n = 16). This was followed by 16 weeks of detraining and another 8 weeks of resistance training. Before the intervention and after each training and detraining period, body composition was assessed by dual-energy X-ray absorptiometry (DXA) and strength was assessed by leg press and bench press 1-repetition maximum (1RM). Results: Clenbuterol increased gains in lean mass (+ 1.7 kg, p < 0.001) and 1RM bench press (+ 6 kg, p < 0.001) and leg press (+ 16 kg, p = 0.001) during 8 weeks of resistance training compared with placebo, with a more pronounced effect in males than females (lean mass: p = 0.003; 1RM bench press: p < 0.001), whereas the decrease in fat mass did not differ between clenbuterol and placebo ( p = 0.614). Following cessation of clenbuterol, detraining decreased lean mass ( p < 0.001), 1RM bench press ( p < 0.001), and 1RM leg press ( p = 0.026) to a greater extent in the clenbuterol group, such that initial changes in lean mass ( p = 0.363) and 1RM bench press ( p = 0.834) no longer differed from placebo, whereas 1RM leg press remained elevated in the clenbuterol group ( p = 0.041). Retraining increased lean mass and 1RM leg press with no differences between the clenbuterol and placebo group (lean mass: p = 0.393; 1RM leg press: p = 0.662), whereas the increase in 1RM bench press was greater in the clenbuterol group (+ 3 kg, p = 0.047). Conclusion: Clenbuterol markedly augments training-induced gains in lean mass and strength. After discontinuation, prior clenbuterol exposure does not enhance retraining-induced lean mass gains, but some strength-related advantages persist. Trial Registration: ClinicalTrials.gov identifier, NCT05692856.
- Open Access
- 25 January 2026
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 17 (1) , e70175
Fibre Type–Specific Proteomics Reveals Shared and Distinct Skeletal Muscle Adaptations to Resistance Training and Beta 2 ‐Adrenergic Agonist
Background: Skeletal muscle is essential for metabolic health and physical function. While resistance training promotes muscle hypertrophy, alternative therapeutic strategies are needed for individuals unable to engage in physical activity. Because beta 2 ‐adrenergic stimulation induces muscle growth without mechanical load, we assessed muscle fibre type–specific proteomic adaptations to prolonged beta 2 ‐adrenergic stimulation and resistance training to decipher shared and distinct remodelling patterns. Methods: We collected vastus lateralis biopsies from 21 moderately trained young males (mean ± SD, age: 24 ± 3) before and after 4‐week whole‐body resistance training (three sessions/week) or daily inhalation of beta 2 ‐adrenergic agonist terbutaline (4 mg/day). From each biopsy, we isolated 40 muscle fibres and typified them using myosin‐heavy‐chain markers. Fibre pools were analysed using LC–MS/MS‐based proteomics. Results: Beta 2 ‐adrenergic stimulation and resistance training both increased peak‐power output during bike‐ergometer sprinting (+36 W; 95% CI: 11 to 61, p = 0.007 and +27 W; 95% CI: −1 to 56, p = 0.062, respectively) with no between‐treatments differences (treatment × time interaction: p = 0.644). Beta 2 ‐adrenergic stimulation regulated 15 and 23 proteins in Type I and Type II fibres, respectively, compared to 101 and 65 with resistance training. There was a remarkable fibre type–dependent response, with ~7% of regulated proteins shared between Type I and Type II fibres with resistance training and ~3% with beta 2 ‐adrenergic stimulation. Both interventions increased abundance of ribosomal proteins, in which resistance training induced a 25% increase in Type I fibres ( p < 0.001) but only 3% in Type II ( p = 0.374), while beta 2 ‐adrenergic stimulation increased ribosomal proteins in both fibre types (Type I: 6% increase, p = 0.008; Type II: 9% increase, p < 0.001). Mitochondrial electron‐transport‐chain protein abundances decreased with both interventions: resistance training reduced abundances mainly in Type I fibres (17% decrease, p < 0.001; Type II: 5% decrease, p = 0.147), while beta 2 ‐adrenergic stimulation caused uniform decreases (Type I: 7% decrease, p = 0.018; Type II: 9% decrease, p = 0.001). Resistance training uniquely increased contractile, cytoskeletal and extracellular matrix proteins, which was not mimicked by beta 2 ‐adrenergic stimulation. S100A13 was upregulated across both interventions and fibre types, whereas MUSTN1 was regulated exclusively with resistance training. Knock‐down of S100a13 (−52%; p < 0.001) and Mustn1 (−96%; p < 0.001) in C2C12 myotubes impaired myotube formation (fusion index: S100a13: −5%; p = 0.002; Mustn1: −21%; p < 0.001). Conclusions: Beta 2 ‐adrenergic stimulation induces proteomic adaptations that partially mimic resistance training, particularly in ribosomal proteins. Shared regulation of S100A13 and unique regulation of MUSTN1 with resistance training suggest distinct and complementary roles in regulating muscle growth. These findings indicate that the beta 2 ‐adrenergic receptor is a potential target to counter muscle atrophic conditions, offering a pharmacological approach for individuals unable to engage in resistance training.
- 25 January 2026
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 17 (1) , e70175
Open AccessFibre Type–Specific Proteomics Reveals Shared and Distinct Skeletal Muscle Adaptations to Resistance Training and Beta 2 ‐Adrenergic Agonist
Background: Skeletal muscle is essential for metabolic health and physical function. While resistance training promotes muscle hypertrophy, alternative therapeutic strategies are needed for individuals unable to engage in physical activity. Because beta 2 ‐adrenergic stimulation induces muscle growth without mechanical load, we assessed muscle fibre type–specific proteomic adaptations to prolonged beta 2 ‐adrenergic stimulation and resistance training to decipher shared and distinct remodelling patterns. Methods: We collected vastus lateralis biopsies from 21 moderately trained young males (mean ± SD, age: 24 ± 3) before and after 4‐week whole‐body resistance training (three sessions/week) or daily inhalation of beta 2 ‐adrenergic agonist terbutaline (4 mg/day). From each biopsy, we isolated 40 muscle fibres and typified them using myosin‐heavy‐chain markers. Fibre pools were analysed using LC–MS/MS‐based proteomics. Results: Beta 2 ‐adrenergic stimulation and resistance training both increased peak‐power output during bike‐ergometer sprinting (+36 W; 95% CI: 11 to 61, p = 0.007 and +27 W; 95% CI: −1 to 56, p = 0.062, respectively) with no between‐treatments differences (treatment × time interaction: p = 0.644). Beta 2 ‐adrenergic stimulation regulated 15 and 23 proteins in Type I and Type II fibres, respectively, compared to 101 and 65 with resistance training. There was a remarkable fibre type–dependent response, with ~7% of regulated proteins shared between Type I and Type II fibres with resistance training and ~3% with beta 2 ‐adrenergic stimulation. Both interventions increased abundance of ribosomal proteins, in which resistance training induced a 25% increase in Type I fibres ( p < 0.001) but only 3% in Type II ( p = 0.374), while beta 2 ‐adrenergic stimulation increased ribosomal proteins in both fibre types (Type I: 6% increase, p = 0.008; Type II: 9% increase, p < 0.001). Mitochondrial electron‐transport‐chain protein abundances decreased with both interventions: resistance training reduced abundances mainly in Type I fibres (17% decrease, p < 0.001; Type II: 5% decrease, p = 0.147), while beta 2 ‐adrenergic stimulation caused uniform decreases (Type I: 7% decrease, p = 0.018; Type II: 9% decrease, p = 0.001). Resistance training uniquely increased contractile, cytoskeletal and extracellular matrix proteins, which was not mimicked by beta 2 ‐adrenergic stimulation. S100A13 was upregulated across both interventions and fibre types, whereas MUSTN1 was regulated exclusively with resistance training. Knock‐down of S100a13 (−52%; p < 0.001) and Mustn1 (−96%; p < 0.001) in C2C12 myotubes impaired myotube formation (fusion index: S100a13: −5%; p = 0.002; Mustn1: −21%; p < 0.001). Conclusions: Beta 2 ‐adrenergic stimulation induces proteomic adaptations that partially mimic resistance training, particularly in ribosomal proteins. Shared regulation of S100A13 and unique regulation of MUSTN1 with resistance training suggest distinct and complementary roles in regulating muscle growth. These findings indicate that the beta 2 ‐adrenergic receptor is a potential target to counter muscle atrophic conditions, offering a pharmacological approach for individuals unable to engage in resistance training.
- Open Access
- 15 December 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (4) , 369-379
The Global Airways in Practice: Long‐term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery (FESS) primarily addresses sinonasal disease and can improve asthma control. The combined effect on airway outcomes remains unclear. This study evaluated the global airway hypothesis with objective measures and targeted therapies. Objective: To investigate the impact of mepolizumab, with or without FESS, on airway inflammation, lung function, and symptom burden in severe CRSwNP with or without asthma. Methods: In this RCT, 58 patients received either mepolizumab alone or combined with FESS. Inflammation and symptom outcomes were analyzed in blood, nose, and bronchi at baseline, six, and 12 months. Patients were stratified by baseline inflammatory subgroup. Results: Both groups showed improvements in FEV1% (MepoFESS: +3.4%, p = 0.010; Mepo Only: +3.5%, p = 0.015), FVC% (MepoFESS: +3.7%, p < 0.001; Mepo Only: +2.9%, p = 0.009), inflammation markers (FeNO, blood eosinophils, nasal polyp eosinophils), and all patient‐reported outcomes. MepoFESS produced greater gains in nasal polyp score, nasal congestion, and overall symptom burden. Lung function and systemic inflammation improved similarly in both groups. Conclusions: Mepolizumab improves upper and lower airway outcomes in CRSwNP. FESS adds localized benefits in sinonasal symptom control without further impact on lower airway inflammation. Findings support a comprehensive approach targeting systemic and local type 2 inflammation in global airway disease.
- 15 December 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (4) , 369-379
Open AccessThe Global Airways in Practice: Long‐term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery (FESS) primarily addresses sinonasal disease and can improve asthma control. The combined effect on airway outcomes remains unclear. This study evaluated the global airway hypothesis with objective measures and targeted therapies. Objective: To investigate the impact of mepolizumab, with or without FESS, on airway inflammation, lung function, and symptom burden in severe CRSwNP with or without asthma. Methods: In this RCT, 58 patients received either mepolizumab alone or combined with FESS. Inflammation and symptom outcomes were analyzed in blood, nose, and bronchi at baseline, six, and 12 months. Patients were stratified by baseline inflammatory subgroup. Results: Both groups showed improvements in FEV1% (MepoFESS: +3.4%, p = 0.010; Mepo Only: +3.5%, p = 0.015), FVC% (MepoFESS: +3.7%, p < 0.001; Mepo Only: +2.9%, p = 0.009), inflammation markers (FeNO, blood eosinophils, nasal polyp eosinophils), and all patient‐reported outcomes. MepoFESS produced greater gains in nasal polyp score, nasal congestion, and overall symptom burden. Lung function and systemic inflammation improved similarly in both groups. Conclusions: Mepolizumab improves upper and lower airway outcomes in CRSwNP. FESS adds localized benefits in sinonasal symptom control without further impact on lower airway inflammation. Findings support a comprehensive approach targeting systemic and local type 2 inflammation in global airway disease.
- Open Access
- 14 September 2025
- Published by Wiley in The Journal of Physiology
- Vol. 603 (19) , 5529-5545
Clenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle β2‐adrenergic signalling
The β2‐adrenergic agonist clenbuterol is widely abused because of its purported fat‐burning actions, muscle accretion properties and performance enhancing effects, and yet it remains unexplored in randomized controlled trials. In the present study, we subjected 11 healthy men (aged 18–40 years) to two 2 week cycles of oral clenbuterol (80 µg day−1) or placebo, separated by a 3 week washout. During each cycle, we assessed body composition, cardiorespiratory fitness, sprint power output, cardiac left ventricular mass and intravascular blood volume. We obtained vastus lateralis muscle biopsies and analysed them for protein content, 3‐hydroxyacyl CoA dehydrogenase (HAD) activity, oxidative phosphorylation complex (OXPHOS) abundance, platelet endothelial cell adhesion molecule (PECAM‐1) abundance and β2‐adrenergic signalling. Compared to placebo, clenbuterol induced a 0.91 kg lean mass gain (95% confidence interval = 0.02–1.81, P < 0.05) but had no effect on fat mass. Clenbuterol reduced maximal oxygen uptake by 7% (P < 0.001) and exercise capacity by 4% (P < 0.001) but had no effects on sprint power output, left ventricular mass, intravascular blood volume or haemoglobin mass. Clenbuterol increased muscle protein content (P < 0.05) and PECAM‐1 abundance (P < 0.05) but repressed HAD activity (P < 0.01) and OXPHOS complex V abundance (P < 0.05). Clenbuterol markedly activated muscle protein kinase A (P < 0.001) and phosphorylated ribosomal protein S6 (Ser235/236) but this effect declined during the 2 week cycle. Although a 2 week clenbuterol cycle effectively induces lean mass gain and muscle protein accretion, it negatively affects cardiorespiratory fitness, represses muscle oxidative capacity, and induces tolerance in β2‐adrenergic signalling and ribosomal protein S6 phosphorylation. The adverse effects of clenbuterol along with its muscle anabolic actions justify its prohibition in elite sports. image Key points: Clenbuterol, a potent β2‐adrenergic agonist, has purported fat‐burning and muscle accretion properties. However, its purported effects, along with its potential adverse effects on cardiorespiratory fitness, remain unexplored in humans. A short 2 week clenbuterol cycle induces lean mass gain and muscle protein accretion in healthy young men. Clenbuterol induces β2‐adrenergic signalling and phosphorylates RpS6Ser235/236 in skeletal muscle, but this signalling response is attenuated with repeated exposure. Clenbuterol negatively affects cardiorespiratory fitness and represses muscle oxidative capacity. Clenbuterol does not affect left ventricular mass, intravascular blood volume or haemoglobin mass.
- 14 September 2025
- Published by Wiley in The Journal of Physiology
- Vol. 603 (19) , 5529-5545
Open AccessClenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle β2‐adrenergic signalling
The β2‐adrenergic agonist clenbuterol is widely abused because of its purported fat‐burning actions, muscle accretion properties and performance enhancing effects, and yet it remains unexplored in randomized controlled trials. In the present study, we subjected 11 healthy men (aged 18–40 years) to two 2 week cycles of oral clenbuterol (80 µg day−1) or placebo, separated by a 3 week washout. During each cycle, we assessed body composition, cardiorespiratory fitness, sprint power output, cardiac left ventricular mass and intravascular blood volume. We obtained vastus lateralis muscle biopsies and analysed them for protein content, 3‐hydroxyacyl CoA dehydrogenase (HAD) activity, oxidative phosphorylation complex (OXPHOS) abundance, platelet endothelial cell adhesion molecule (PECAM‐1) abundance and β2‐adrenergic signalling. Compared to placebo, clenbuterol induced a 0.91 kg lean mass gain (95% confidence interval = 0.02–1.81, P < 0.05) but had no effect on fat mass. Clenbuterol reduced maximal oxygen uptake by 7% (P < 0.001) and exercise capacity by 4% (P < 0.001) but had no effects on sprint power output, left ventricular mass, intravascular blood volume or haemoglobin mass. Clenbuterol increased muscle protein content (P < 0.05) and PECAM‐1 abundance (P < 0.05) but repressed HAD activity (P < 0.01) and OXPHOS complex V abundance (P < 0.05). Clenbuterol markedly activated muscle protein kinase A (P < 0.001) and phosphorylated ribosomal protein S6 (Ser235/236) but this effect declined during the 2 week cycle. Although a 2 week clenbuterol cycle effectively induces lean mass gain and muscle protein accretion, it negatively affects cardiorespiratory fitness, represses muscle oxidative capacity, and induces tolerance in β2‐adrenergic signalling and ribosomal protein S6 phosphorylation. The adverse effects of clenbuterol along with its muscle anabolic actions justify its prohibition in elite sports. image Key points: Clenbuterol, a potent β2‐adrenergic agonist, has purported fat‐burning and muscle accretion properties. However, its purported effects, along with its potential adverse effects on cardiorespiratory fitness, remain unexplored in humans. A short 2 week clenbuterol cycle induces lean mass gain and muscle protein accretion in healthy young men. Clenbuterol induces β2‐adrenergic signalling and phosphorylates RpS6Ser235/236 in skeletal muscle, but this signalling response is attenuated with repeated exposure. Clenbuterol negatively affects cardiorespiratory fitness and represses muscle oxidative capacity. Clenbuterol does not affect left ventricular mass, intravascular blood volume or haemoglobin mass.
- Top Cited PapersOpen Access
- 9 August 2025
- Published by Wiley in Scandinavian Journal of Medicine & Science in Sports
- Vol. 35 (8) , e70112
Consensus Statements—Optimizing Performance of the Elite Athlete
The International Consensus Conference “Optimising Performance of the Elite Athlete,” held in November 2024, brought together 29 scientists, some coaches, and athletes to establish evidence‐based consensus statements aimed at enhancing elite athletic performance and health. The conference addressed critical themes including training strategies, nutrition, female athlete considerations, injury management, and emerging technologies. Key conclusions emphasize individualized, sport‐specific approaches to training and nutrition, integrating concurrent training modalities to improve endurance, resilience, and efficiency. Nutrition strategies highlight the importance of tailored energy and macronutrient periodization, recognition of low energy availability risks, and cautious use of dietary supplements. Special attention was directed to female athletes, advocating for improved monitoring of menstrual cycles and hormonal status, while acknowledging current knowledge gaps in hormonal influences on performance and injury risk. Injury prevention remains a challenge, with tendon overuse and Achilles tendon ruptures significantly impacting athlete careers; rehabilitation should rely on criteria‐based progression and multidisciplinary input. Emerging technologies, including wearable sensors and multi‐omics analyses, hold promise for personalized training and nutrition but require further validation in elite contexts. Despite robust consensus, the panel identified substantial research gaps, particularly regarding female athletes, longitudinal training effects, and efficacy of novel interventions. This consensus provides a practical, scientifically grounded framework to optimize elite athlete performance and health, while underscoring the need for continued research to address outstanding questions and promote inclusive evidence‐based practices.
- 9 August 2025
- Published by Wiley in Scandinavian Journal of Medicine & Science in Sports
- Vol. 35 (8) , e70112
Top Cited PapersOpen AccessConsensus Statements—Optimizing Performance of the Elite Athlete
The International Consensus Conference “Optimising Performance of the Elite Athlete,” held in November 2024, brought together 29 scientists, some coaches, and athletes to establish evidence‐based consensus statements aimed at enhancing elite athletic performance and health. The conference addressed critical themes including training strategies, nutrition, female athlete considerations, injury management, and emerging technologies. Key conclusions emphasize individualized, sport‐specific approaches to training and nutrition, integrating concurrent training modalities to improve endurance, resilience, and efficiency. Nutrition strategies highlight the importance of tailored energy and macronutrient periodization, recognition of low energy availability risks, and cautious use of dietary supplements. Special attention was directed to female athletes, advocating for improved monitoring of menstrual cycles and hormonal status, while acknowledging current knowledge gaps in hormonal influences on performance and injury risk. Injury prevention remains a challenge, with tendon overuse and Achilles tendon ruptures significantly impacting athlete careers; rehabilitation should rely on criteria‐based progression and multidisciplinary input. Emerging technologies, including wearable sensors and multi‐omics analyses, hold promise for personalized training and nutrition but require further validation in elite contexts. Despite robust consensus, the panel identified substantial research gaps, particularly regarding female athletes, longitudinal training effects, and efficacy of novel interventions. This consensus provides a practical, scientifically grounded framework to optimize elite athlete performance and health, while underscoring the need for continued research to address outstanding questions and promote inclusive evidence‐based practices.
- Top Cited PapersOpen Access
- 19 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Human skeletal muscle fiber heterogeneity beyond myosin heavy chains
Skeletal muscle is a heterogenous tissue comprised primarily of myofibers, commonly classified into three fiber types in humans: one “slow” (type 1) and two “fast” (type 2A and type 2X). However, heterogeneity between and within traditional fiber types remains underexplored. We applied transcriptomic and proteomic workflows to 1050 and 1038 single myofibers from human vastus lateralis, respectively. Proteomics was conducted in males, while transcriptomics included ten males and two females. We identify metabolic, ribosomal, and cell junction proteins, in addition to myosin heavy chain isoforms, as sources of multi-dimensional variation between myofibers. Furthermore, whilst slow and fast fiber clusters are identified, our data suggests that type 2X fibers are not phenotypically distinct to other fast fibers. Moreover, myosin heavy chain-based classifications do not adequately describe the phenotype of myofibers in nemaline myopathy. Overall, our data indicates that myofiber heterogeneity is multi-dimensional with sources of variation beyond myosin heavy chain isoforms.
- 19 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Top Cited PapersOpen AccessHuman skeletal muscle fiber heterogeneity beyond myosin heavy chains
Skeletal muscle is a heterogenous tissue comprised primarily of myofibers, commonly classified into three fiber types in humans: one “slow” (type 1) and two “fast” (type 2A and type 2X). However, heterogeneity between and within traditional fiber types remains underexplored. We applied transcriptomic and proteomic workflows to 1050 and 1038 single myofibers from human vastus lateralis, respectively. Proteomics was conducted in males, while transcriptomics included ten males and two females. We identify metabolic, ribosomal, and cell junction proteins, in addition to myosin heavy chain isoforms, as sources of multi-dimensional variation between myofibers. Furthermore, whilst slow and fast fiber clusters are identified, our data suggests that type 2X fibers are not phenotypically distinct to other fast fibers. Moreover, myosin heavy chain-based classifications do not adequately describe the phenotype of myofibers in nemaline myopathy. Overall, our data indicates that myofiber heterogeneity is multi-dimensional with sources of variation beyond myosin heavy chain isoforms.
- Open Access
Muscle fiber proteomics reveals sex- and fiber type-specific adaptations to resistance training
Skeletal muscle hypertrophy is a hallmark of resistance training that positively impacts health and longevity. However, despite physiological differences between sexes and fiber types, the underlying proteome changes with resistance training have not been studied in a sex- and fiber type-specific manner. Herein, we show sex differences in the fiber type-specific proteome, predominantly in type II fibers. Following 8 weeks of resistance training, substantial remodeling of the human skeletal muscle proteome occurred in a sex- and fiber type-specific manner. Notably, type II fibers exhibited much greater adaptations across both sexes, whereas the main sex-difference was a greater remodeling of intermediate filaments in females. In addition, baseline abundance of proteins involved in translation was highly correlated with fiber hypertrophy, and differed between sexes and fiber types. Thus, translational capacity may partially explain differences in resistance training-induced hypertrophy. Our findings demonstrate key aspects of sex- and fiber type differences in muscle physiology and their contributions to resistance training-induced adaptions.
Open AccessMuscle fiber proteomics reveals sex- and fiber type-specific adaptations to resistance training
Skeletal muscle hypertrophy is a hallmark of resistance training that positively impacts health and longevity. However, despite physiological differences between sexes and fiber types, the underlying proteome changes with resistance training have not been studied in a sex- and fiber type-specific manner. Herein, we show sex differences in the fiber type-specific proteome, predominantly in type II fibers. Following 8 weeks of resistance training, substantial remodeling of the human skeletal muscle proteome occurred in a sex- and fiber type-specific manner. Notably, type II fibers exhibited much greater adaptations across both sexes, whereas the main sex-difference was a greater remodeling of intermediate filaments in females. In addition, baseline abundance of proteins involved in translation was highly correlated with fiber hypertrophy, and differed between sexes and fiber types. Thus, translational capacity may partially explain differences in resistance training-induced hypertrophy. Our findings demonstrate key aspects of sex- and fiber type differences in muscle physiology and their contributions to resistance training-induced adaptions.
- Open Access
- 22 April 2024
- Published by Wiley in Scandinavian Journal of Medicine & Science in Sports
- Vol. 34 (4) , e14629
No additive effect of creatine, caffeine, and sodium bicarbonate on intense exercise performance in endurance‐trained individuals
Background: Athletes commonly use creatine, caffeine, and sodium bicarbonate for performance enhancement. While their isolated effects are well‐described, less is known about their potential additive effects. Methods: Following a baseline trial, we randomized 12 endurance‐trained males (age: 25 ± 5 years, VO 2max : 56.7 ± 4.6 mL kg −1 min −1 ; mean ± SD) and 11 females (age: 25 ± 3 years, VO 2max : 50.2 ± 3.4 mL kg −1 min −1 ) to 5 days of creatine monohydrate (0.3 g kg −1 per day) or placebo loading, followed by a daily maintenance dose (0.04 g kg −1 ) throughout the study. After the loading period, subjects completed four trials in randomized order where they ingested caffeine (3 mg kg −1 ), sodium bicarbonate (0.3 g kg −1 ), placebo, or both caffeine and sodium bicarbonate before a maximal voluntary contraction (MVC), 15‐s sprint, and 6‐min time trial. Results: Compared to placebo, mean power output during 15‐s sprint was higher following loading with creatine than placebo (+34 W, 95% CI: 10 to 58, p = 0.008), but with no additional effect of caffeine (+10 W, 95% CI: −7 to 24, p = 0.156) or sodium bicarbonate (+5 W, 95% CI: −4 to 13, p = 0.397). Mean power output during 6‐min time trial was higher with caffeine (+12 W, 95% CI: 5 to 18, p = 0.001) and caffeine + sodium bicarbonate (+8 W, 95% CI: 0 to 15, p = 0.038), whereas sodium bicarbonate (–1 W, 95% CI: −7 to 6, p = 0.851) and creatine (–6 W, 95% CI: −15 to 4, p = 0.250) had no effects. Conclusion: While creatine and caffeine can enhance sprint‐ and time trial performance, respectively, these effects do not seem additive. Therefore, supplementing with either creatine or caffeine appears sufficient to enhance sprint or short intense exercise performance.
- 22 April 2024
- Published by Wiley in Scandinavian Journal of Medicine & Science in Sports
- Vol. 34 (4) , e14629
Open AccessNo additive effect of creatine, caffeine, and sodium bicarbonate on intense exercise performance in endurance‐trained individuals
Background: Athletes commonly use creatine, caffeine, and sodium bicarbonate for performance enhancement. While their isolated effects are well‐described, less is known about their potential additive effects. Methods: Following a baseline trial, we randomized 12 endurance‐trained males (age: 25 ± 5 years, VO 2max : 56.7 ± 4.6 mL kg −1 min −1 ; mean ± SD) and 11 females (age: 25 ± 3 years, VO 2max : 50.2 ± 3.4 mL kg −1 min −1 ) to 5 days of creatine monohydrate (0.3 g kg −1 per day) or placebo loading, followed by a daily maintenance dose (0.04 g kg −1 ) throughout the study. After the loading period, subjects completed four trials in randomized order where they ingested caffeine (3 mg kg −1 ), sodium bicarbonate (0.3 g kg −1 ), placebo, or both caffeine and sodium bicarbonate before a maximal voluntary contraction (MVC), 15‐s sprint, and 6‐min time trial. Results: Compared to placebo, mean power output during 15‐s sprint was higher following loading with creatine than placebo (+34 W, 95% CI: 10 to 58, p = 0.008), but with no additional effect of caffeine (+10 W, 95% CI: −7 to 24, p = 0.156) or sodium bicarbonate (+5 W, 95% CI: −4 to 13, p = 0.397). Mean power output during 6‐min time trial was higher with caffeine (+12 W, 95% CI: 5 to 18, p = 0.001) and caffeine + sodium bicarbonate (+8 W, 95% CI: 0 to 15, p = 0.038), whereas sodium bicarbonate (–1 W, 95% CI: −7 to 6, p = 0.851) and creatine (–6 W, 95% CI: −15 to 4, p = 0.250) had no effects. Conclusion: While creatine and caffeine can enhance sprint‐ and time trial performance, respectively, these effects do not seem additive. Therefore, supplementing with either creatine or caffeine appears sufficient to enhance sprint or short intense exercise performance.
- 1 September 2022
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 133 (3) , 732-741
Myonuclear addition is associated with sex-specific fiber hypertrophy and occurs in relation to fiber perimeter not cross-sectional area
It is unclear whether resistance training-induced myofiber hypertrophy is affected by sex, and whether myonuclear addition occurs in relation to the myonuclear domain and can contribute to explaining a potential sex-specific hypertrophic response. This study investigated the effect of 8 wk of resistance training on myofiber hypertrophy and myonuclear addition in 12 males (28 ± 7 yr; mean ± SD) and 12 females (27 ± 7 yr). Muscle biopsies were collected from m. vastus lateralis before and after the training intervention and were analyzed by immunohistochemistry for fiber type and size, satellite cells, and myonuclei. Hypertrophy of type I fibers was greater in males than females (P < 0.05), whereas hypertrophy of type II fibers was similar between sexes (P = 0.158–0.419). Expansion of the satellite cell pool (P = 0.132–0.667) and myonuclear addition (P = 0.064–0.228) did not differ significantly between sexes, irrespective of myofiber type. However, when individual responses to resistance training were assessed, myonuclear addition was strongly correlated with fiber hypertrophy (r = 0.68–0.85, P < 0.001). Although myofiber hypertrophy was accompanied by an increase in myonuclear domain (P < 0.05), fiber perimeter per myonucleus remained constant throughout the study (P = 0.096–0.666). These findings indicate that myonuclear addition occurs in relation to the fiber perimeter per myonucleus, not the myonuclear domain, and has a substantial role in resistance training-induced muscle hypertrophy but does not fully explain greater hypertrophy of type I fibers in males than females. NEW & NOTEWORTHY Here, we show that resistance training-induced hypertrophy of type I fibers is greater in males than females. Myonuclear addition was strongly associated with fiber hypertrophy but did not differ between sexes in type I fibers. Furthermore, whereas muscle hypertrophy was accompanied by an increase in myonuclear domain, fiber perimeter per myonucleus remained constant. Thus, myonuclear addition occurs in relation to fiber perimeter during muscle hypertrophy but does not explain sex-specific hypertrophy of type I fibers.
- 1 September 2022
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 133 (3) , 732-741
Myonuclear addition is associated with sex-specific fiber hypertrophy and occurs in relation to fiber perimeter not cross-sectional area
It is unclear whether resistance training-induced myofiber hypertrophy is affected by sex, and whether myonuclear addition occurs in relation to the myonuclear domain and can contribute to explaining a potential sex-specific hypertrophic response. This study investigated the effect of 8 wk of resistance training on myofiber hypertrophy and myonuclear addition in 12 males (28 ± 7 yr; mean ± SD) and 12 females (27 ± 7 yr). Muscle biopsies were collected from m. vastus lateralis before and after the training intervention and were analyzed by immunohistochemistry for fiber type and size, satellite cells, and myonuclei. Hypertrophy of type I fibers was greater in males than females (P < 0.05), whereas hypertrophy of type II fibers was similar between sexes (P = 0.158–0.419). Expansion of the satellite cell pool (P = 0.132–0.667) and myonuclear addition (P = 0.064–0.228) did not differ significantly between sexes, irrespective of myofiber type. However, when individual responses to resistance training were assessed, myonuclear addition was strongly correlated with fiber hypertrophy (r = 0.68–0.85, P < 0.001). Although myofiber hypertrophy was accompanied by an increase in myonuclear domain (P < 0.05), fiber perimeter per myonucleus remained constant throughout the study (P = 0.096–0.666). These findings indicate that myonuclear addition occurs in relation to the fiber perimeter per myonucleus, not the myonuclear domain, and has a substantial role in resistance training-induced muscle hypertrophy but does not fully explain greater hypertrophy of type I fibers in males than females. NEW & NOTEWORTHY Here, we show that resistance training-induced hypertrophy of type I fibers is greater in males than females. Myonuclear addition was strongly associated with fiber hypertrophy but did not differ between sexes in type I fibers. Furthermore, whereas muscle hypertrophy was accompanied by an increase in myonuclear domain, fiber perimeter per myonucleus remained constant. Thus, myonuclear addition occurs in relation to fiber perimeter during muscle hypertrophy but does not explain sex-specific hypertrophy of type I fibers.